Understanding the Caregiver Experience in Dravet Syndrome Clinical Trials

Dravet syndrome is a severe developmental and epileptic encephalopathy beginning in early infancy. Managing this condition requires complex therapeutic approaches because standard antiseizure medications frequently fail. Over recent decades, multiple randomized controlled trials evaluated novel drugs including stiripentol, cannabidiol, fenfluramine, and soticlestat. However, participating in Dravet syndrome clinical trials introduces administrative and psychological demands for families. Caregivers navigate emotional uncertainty while coordinating clinical visit schedules. A cross-sectional survey examined how French families experienced trial participation between 1996 and 2024. Most caregivers reported that treating pediatric neurologists directly proposed trial enrollment. Trusting relationships with medical staff significantly influenced parental decisions to explore experimental therapies. Caregivers primarily sought early access to promising treatments for better seizure control. Understanding caregiver perspectives offers essential insights for improving trial recruitment, protocol design, and participant retention in pediatric neurology.

Key Motivations Driving Participation in Dravet Syndrome Clinical Trials

Caregivers decide to enroll their children in clinical trials for compelling reasons. Primary motivators include gaining early access to novel options, holding hope for seizure reduction, and maintaining deep confidence in medical teams. In many instances, families feel that established antiseizure regimens provide insufficient seizure control. Consequently, novel trial protocols offer a path toward improved health outcomes. Furthermore, parents experience optimism when investigators offer specialized medical monitoring and novel drug candidates. Faith in pediatric neurologists plays a decisive role when parents grant informed consent. When doctors explain potential benefits clearly, caregivers feel empowered during decision-making. Conversely, families who decline enrollment usually report satisfactory seizure control with existing therapies. Some parents miss trial opportunities because studies conclude before awareness develops, while eligibility criteria exclude other candidates. Understanding these motivators helps research teams design patient-centered trials.

Addressing Primary Barriers and Perceived Risks for Families

Although clinical trials offer therapeutic hope, caregivers experience hesitation before enrolling their children. Major reasons for non-participation include intense concerns about potential adverse events, emotional distress caused by clinical uncertainty, and anxiety regarding placebo assignment. Dravet syndrome involves unpredictable, severe convulsive seizures that create ongoing stress for households. Therefore, adding investigational drug risks can feel overwhelming for families. Moreover, parents worry that adverse effects might worsen baseline neurological symptoms or cognitive development. Placebo assignment introduces additional emotional strain, as caregivers fear their child may receive inactive treatment during critical therapeutic windows. Logistical burdens also present major practical obstacles for participating families. Frequent hospital visits, mandatory laboratory testing, and strict dosing protocols disrupt work and school schedules. Long-distance travel to specialized research centers adds financial strain. Research coordinators must address these hurdles by streamlining visit schedules and offering robust support.

Navigating Emotional Waves During Active Clinical Trial Phases

Throughout active trial participation, caregivers experience fluctuating emotional dynamics across study phases. Survey findings show that hope, fear of trial non-completion, and stress dominate parental emotional experiences. Initially, trial enrollment brings renewed optimism regarding potential seizure reduction. However, persistent worry about study discontinuation or investigational drug failure remains prevalent. Caregivers worry that unexpected adverse events or administrative complications might force early withdrawal from the trial protocol. Furthermore, managing daily schedules to accommodate frequent medical appointments generates substantial stress. Caregivers balance routine family duties, job responsibilities, and detailed study documentation. Despite these daily pressures, parents generally rate their overall clinical trial experience positively. Strong support from research staff and treating pediatric neurologists helps mitigate psychological strain. Open communication channels allow caregivers to discuss concerns and receive timely reassurance. Consequently, institutional support structures prove essential for helping families complete trials successfully.

Post-Trial Dynamics and Long-Term Caregiver Support Strategies

The conclusion of a clinical trial marks a significant transition period for participating families. Survey findings revealed that caregiver feelings of post-trial regret and solitude scored remarkably low. This outcome indicates that structured trial environments foster lasting trust and satisfaction among participating families. Caregivers appreciated the specialized medical oversight provided throughout trial duration, even after protocols concluded. However, post-trial transition planning requires careful coordination from treating clinical teams. Once active study phases end, families must transition back to routine medical care or enter open-label extension protocols. Ensuring continued access to effective investigational therapies post-trial remains an essential ethical priority for sponsors and researchers. Moreover, clear communication regarding overall study outcomes helps families process their research journey. When trials fail to meet primary endpoints, transparent discussions prevent parental disillusionment. Investigators should provide ongoing guidance to help caregivers explore future therapeutic options.

Translating Caregiver Insights into Optimized Clinical Trial Protocols

Integrating caregiver feedback into clinical trial design is vital for enhancing recruitment, participant retention, and overall trial acceptance. Pediatric epilepsy studies must prioritize family-centered protocols that minimize daily operational burdens. For example, incorporating decentralized trial options, such as telehealth visits and local laboratory testing, can significantly reduce family travel stress. Furthermore, research teams should refine communication strategies regarding prospective placebo assignment and adverse event management. Clear dialogue reduces parental anxiety and fosters realistic expectations from the outset. Engaging patient advocacy organizations during trial planning ensures that clinical endpoints align with meaningful real-world family outcomes. When study protocols reflect caregiver realities, recruitment efficiency improves and drop-out rates decline. Additionally, understanding caregiver motivations enables physicians to discuss clinical trials effectively during routine pediatric neurology consultations. Neurologists should provide balanced information addressing specific parental concerns. Ultimately, collaborative partnerships between clinicians, researchers, and families will advance safer therapies for Dravet syndrome.

Frequently Asked Questions

What are the primary reasons caregivers enroll children with Dravet syndrome into clinical trials?

Caregivers primarily choose trial enrollment to gain early access to innovative therapies, driven by hope for better seizure control and confidence in their medical team. In refractory Dravet syndrome, standard antiseizure medications often yield unsatisfactory clinical results. Consequently, families see clinical research as a vital pathway toward improved therapeutic outcomes and dedicated specialist oversight throughout their child's treatment journey.

What key obstacles discourage families from participating in pediatric epilepsy clinical trials?

Main barriers preventing trial participation include significant fears regarding adverse events, anxiety about receiving a placebo, and emotional stress linked to clinical uncertainty. Additionally, demanding daily schedules required for regular medical appointments, frequent blood sampling, and long-distance travel to clinical research centers create substantial operational strain for families caring for a child with severe epilepsy, often forcing parents to balance employment and caregiving duties.

How can research teams improve caregiver experiences during rare disease clinical trials?

Research teams can optimize trial experiences by offering clear, transparent communication regarding potential risks and placebo protocols. Implementing flexible visit schedules, utilizing decentralized study tools, and providing continuous emotional support significantly ease parental burden throughout the trial. Furthermore, ensuring transparent post-trial transitions and clear sharing of overall study outcomes helps maintain long-term caregiver trust and engagement across future research initiatives.

Disclaimer: This content is for informational and educational purposes only, intended for healthcare professionals, and should not replace clinical judgment or official guidelines. Refer to the latest local and national guidelines for clinical practice.

References

1. Delattre C et al. Exploring the caregiver journey through randomized controlled trials in dravet syndrome: insights from a cross-sectional survey. Epilepsy Behav. 2026 Aug 08. doi: undefined. PMID: 42570405.


2. Juando-Prats C et al. DRAVET ENGAGE. Parent caregivers of children with Dravet syndrome: Perspectives, needs, and opportunities for clinical research. Epilepsy Behav. 2021 Sep;122:108198.


3. Nabbout R et al. Practical consensus recommendations for polytherapy involving stiripentol in Dravet syndrome: A nominal group approach. Epilepsia Open. 2026;11(1):e12923.